

Global Tumor Immune Cell Therapy Market 2026 by Company, Regions, Type and Application, Forecast to 2032

<https://marketpublishers.com/r/G487C1DD8422EN.html>

Date: January 2026

Pages: 131

Price: US\$ 3,480.00 (Single User License)

ID: G487C1DD8422EN

Abstracts

According to our (Global Info Research) latest study, the global Tumor Immune Cell Therapy market size was valued at US\$ million in 2025 and is forecast to a readjusted size of US\$ million by 2032 with a CAGR of %during review period.

Cancer immune cell therapy is a treatment method that activates the function of the patient's own immune cells, thereby enhancing the immune cells' ability to attack cancer and inhibit cancer cells. In actual treatment, we extract immune cells involved in attacking cancer from the patient's blood, cancer tissue, ascites, and pleural effusion, proliferate, activate, and enhance their functions in vitro before returning them to the patient.

This report is a detailed and comprehensive analysis for global Tumor Immune Cell Therapy market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Tumor Immune Cell Therapy market size and forecasts, in consumption value (\$ Million), 2021-2032

Global Tumor Immune Cell Therapy market size and forecasts by region and country, in

consumption value (\$ Million), 2021-2032

Global Tumor Immune Cell Therapy market size and forecasts, by Type and by Application, in consumption value (\$ Million), 2021-2032

Global Tumor Immune Cell Therapy market shares of main players, in revenue (\$ Million), 2021-2026

The Primary Objectives in This Report Are:

- To determine the size of the total market opportunity of global and key countries
- To assess the growth potential for Tumor Immune Cell Therapy
- To forecast future growth in each product and end-use market
- To assess competitive factors affecting the marketplace

This report profiles key players in the global Tumor Immune Cell Therapy market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include MEDINET Co, Erytech, Seta Clinic Group, Takeda, SBI Holdings, Oxford BioTherapeutics, Fate Therapeutics, Gilead Sciences, Novartis, Osiris, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market segmentation

Tumor Immune Cell Therapy market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

Immune Checkpoint Inhibitors

Chimeric Antigen Receptor T-cell Therapy

Tumor-Infiltrating Lymphocytes Therapy

Cancer Vaccines

Bispecific Antibodies

Cytokine Therapy

Market segment by Application

Hematological Tumors

Solid Tumors

Market segment by players, this report covers

MEDINET Co

Erytech

Seta Clinic Group

Takeda

SBI Holdings

Oxford BioTherapeutics

Fate Therapeutics

Gilead Sciences

Novartis

Osiris

Vericel Corporation

Fujifilm Cellular Dynamics

JCR Pharmaceuticals

Beike Biotechnology

Golden Meditech

Guanhao Biotech

Beroni Group

Legend Biotech

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Tumor Immune Cell Therapy product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Tumor Immune Cell Therapy, with revenue, gross margin, and global market share of Tumor Immune Cell Therapy from 2021 to 2026.

Chapter 3, the Tumor Immune Cell Therapy competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with

revenue and market share for key countries in the world, from 2021 to 2026. and Tumor Immune Cell Therapy market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Tumor Immune Cell Therapy.

Chapter 13, to describe Tumor Immune Cell Therapy research findings and conclusion.

Contents

1 MARKET OVERVIEW

1.1 Product Overview and Scope

1.2 Market Estimation Caveats and Base Year

1.3 Classification of Tumor Immune Cell Therapy by Type

1.3.1 Overview: Global Tumor Immune Cell Therapy Market Size by Type: 2021 Versus 2025 Versus 2032

1.3.2 Global Tumor Immune Cell Therapy Consumption Value Market Share by Type in 2025

1.3.3 Immune Checkpoint Inhibitors

1.3.4 Chimeric Antigen Receptor T-cell Therapy

1.3.5 Tumor-Infiltrating Lymphocytes Therapy

1.3.6 Cancer Vaccines

1.3.7 Bispecific Antibodies

1.3.8 Cytokine Therapy

1.4 Global Tumor Immune Cell Therapy Market by Application

1.4.1 Overview: Global Tumor Immune Cell Therapy Market Size by Application: 2021 Versus 2025 Versus 2032

1.4.2 Hematological Tumors

1.4.3 Solid Tumors

1.5 Global Tumor Immune Cell Therapy Market Size & Forecast

1.6 Global Tumor Immune Cell Therapy Market Size and Forecast by Region

1.6.1 Global Tumor Immune Cell Therapy Market Size by Region: 2021 VS 2025 VS 2032

1.6.2 Global Tumor Immune Cell Therapy Market Size by Region, (2021-2032)

1.6.3 North America Tumor Immune Cell Therapy Market Size and Prospect (2021-2032)

1.6.4 Europe Tumor Immune Cell Therapy Market Size and Prospect (2021-2032)

1.6.5 Asia-Pacific Tumor Immune Cell Therapy Market Size and Prospect (2021-2032)

1.6.6 South America Tumor Immune Cell Therapy Market Size and Prospect (2021-2032)

1.6.7 Middle East & Africa Tumor Immune Cell Therapy Market Size and Prospect (2021-2032)

2 COMPANY PROFILES

2.1 MEDINET Co

- 2.1.1 MEDINET Co Details
- 2.1.2 MEDINET Co Major Business
- 2.1.3 MEDINET Co Tumor Immune Cell Therapy Product and Solutions
- 2.1.4 MEDINET Co Tumor Immune Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
- 2.1.5 MEDINET Co Recent Developments and Future Plans
- 2.2 Erytech
 - 2.2.1 Erytech Details
 - 2.2.2 Erytech Major Business
 - 2.2.3 Erytech Tumor Immune Cell Therapy Product and Solutions
 - 2.2.4 Erytech Tumor Immune Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
 - 2.2.5 Erytech Recent Developments and Future Plans
- 2.3 Seta Clinic Group
 - 2.3.1 Seta Clinic Group Details
 - 2.3.2 Seta Clinic Group Major Business
 - 2.3.3 Seta Clinic Group Tumor Immune Cell Therapy Product and Solutions
 - 2.3.4 Seta Clinic Group Tumor Immune Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
 - 2.3.5 Seta Clinic Group Recent Developments and Future Plans
- 2.4 Takeda
 - 2.4.1 Takeda Details
 - 2.4.2 Takeda Major Business
 - 2.4.3 Takeda Tumor Immune Cell Therapy Product and Solutions
 - 2.4.4 Takeda Tumor Immune Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
 - 2.4.5 Takeda Recent Developments and Future Plans
- 2.5 SBI Holdings
 - 2.5.1 SBI Holdings Details
 - 2.5.2 SBI Holdings Major Business
 - 2.5.3 SBI Holdings Tumor Immune Cell Therapy Product and Solutions
 - 2.5.4 SBI Holdings Tumor Immune Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
 - 2.5.5 SBI Holdings Recent Developments and Future Plans
- 2.6 Oxford BioTherapeutics
 - 2.6.1 Oxford BioTherapeutics Details
 - 2.6.2 Oxford BioTherapeutics Major Business
 - 2.6.3 Oxford BioTherapeutics Tumor Immune Cell Therapy Product and Solutions
 - 2.6.4 Oxford BioTherapeutics Tumor Immune Cell Therapy Revenue, Gross Margin

and Market Share (2021-2026)

2.6.5 Oxford BioTherapeutics Recent Developments and Future Plans

2.7 Fate Therapeutics

2.7.1 Fate Therapeutics Details

2.7.2 Fate Therapeutics Major Business

2.7.3 Fate Therapeutics Tumor Immune Cell Therapy Product and Solutions

2.7.4 Fate Therapeutics Tumor Immune Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)

2.7.5 Fate Therapeutics Recent Developments and Future Plans

2.8 Gilead Sciences

2.8.1 Gilead Sciences Details

2.8.2 Gilead Sciences Major Business

2.8.3 Gilead Sciences Tumor Immune Cell Therapy Product and Solutions

2.8.4 Gilead Sciences Tumor Immune Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)

2.8.5 Gilead Sciences Recent Developments and Future Plans

2.9 Novartis

2.9.1 Novartis Details

2.9.2 Novartis Major Business

2.9.3 Novartis Tumor Immune Cell Therapy Product and Solutions

2.9.4 Novartis Tumor Immune Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)

2.9.5 Novartis Recent Developments and Future Plans

2.10 Osiris

2.10.1 Osiris Details

2.10.2 Osiris Major Business

2.10.3 Osiris Tumor Immune Cell Therapy Product and Solutions

2.10.4 Osiris Tumor Immune Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)

2.10.5 Osiris Recent Developments and Future Plans

2.11 Vericel Corporation

2.11.1 Vericel Corporation Details

2.11.2 Vericel Corporation Major Business

2.11.3 Vericel Corporation Tumor Immune Cell Therapy Product and Solutions

2.11.4 Vericel Corporation Tumor Immune Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)

2.11.5 Vericel Corporation Recent Developments and Future Plans

2.12 Fujifilm Cellular Dynamics

2.12.1 Fujifilm Cellular Dynamics Details

- 2.12.2 Fujifilm Cellular Dynamics Major Business
- 2.12.3 Fujifilm Cellular Dynamics Tumor Immune Cell Therapy Product and Solutions
- 2.12.4 Fujifilm Cellular Dynamics Tumor Immune Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
- 2.12.5 Fujifilm Cellular Dynamics Recent Developments and Future Plans
- 2.13 JCR Pharmaceuticals
 - 2.13.1 JCR Pharmaceuticals Details
 - 2.13.2 JCR Pharmaceuticals Major Business
 - 2.13.3 JCR Pharmaceuticals Tumor Immune Cell Therapy Product and Solutions
 - 2.13.4 JCR Pharmaceuticals Tumor Immune Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
 - 2.13.5 JCR Pharmaceuticals Recent Developments and Future Plans
- 2.14 Beike Biotechnology
 - 2.14.1 Beike Biotechnology Details
 - 2.14.2 Beike Biotechnology Major Business
 - 2.14.3 Beike Biotechnology Tumor Immune Cell Therapy Product and Solutions
 - 2.14.4 Beike Biotechnology Tumor Immune Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
 - 2.14.5 Beike Biotechnology Recent Developments and Future Plans
- 2.15 Golden Meditech
 - 2.15.1 Golden Meditech Details
 - 2.15.2 Golden Meditech Major Business
 - 2.15.3 Golden Meditech Tumor Immune Cell Therapy Product and Solutions
 - 2.15.4 Golden Meditech Tumor Immune Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
 - 2.15.5 Golden Meditech Recent Developments and Future Plans
- 2.16 Guanhao Biotech
 - 2.16.1 Guanhao Biotech Details
 - 2.16.2 Guanhao Biotech Major Business
 - 2.16.3 Guanhao Biotech Tumor Immune Cell Therapy Product and Solutions
 - 2.16.4 Guanhao Biotech Tumor Immune Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
 - 2.16.5 Guanhao Biotech Recent Developments and Future Plans
- 2.17 Beroni Group
 - 2.17.1 Beroni Group Details
 - 2.17.2 Beroni Group Major Business
 - 2.17.3 Beroni Group Tumor Immune Cell Therapy Product and Solutions
 - 2.17.4 Beroni Group Tumor Immune Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)

- 2.17.5 Beroni Group Recent Developments and Future Plans
- 2.18 Legend Biotech
 - 2.18.1 Legend Biotech Details
 - 2.18.2 Legend Biotech Major Business
 - 2.18.3 Legend Biotech Tumor Immune Cell Therapy Product and Solutions
 - 2.18.4 Legend Biotech Tumor Immune Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
 - 2.18.5 Legend Biotech Recent Developments and Future Plans

3 MARKET COMPETITION, BY PLAYERS

- 3.1 Global Tumor Immune Cell Therapy Revenue and Share by Players (2021-2026)
- 3.2 Market Share Analysis (2025)
 - 3.2.1 Market Share of Tumor Immune Cell Therapy by Company Revenue
 - 3.2.2 Top 3 Tumor Immune Cell Therapy Players Market Share in 2025
 - 3.2.3 Top 6 Tumor Immune Cell Therapy Players Market Share in 2025
- 3.3 Tumor Immune Cell Therapy Market: Overall Company Footprint Analysis
 - 3.3.1 Tumor Immune Cell Therapy Market: Region Footprint
 - 3.3.2 Tumor Immune Cell Therapy Market: Company Product Type Footprint
 - 3.3.3 Tumor Immune Cell Therapy Market: Company Product Application Footprint
- 3.4 New Market Entrants and Barriers to Market Entry
- 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 MARKET SIZE SEGMENT BY TYPE

- 4.1 Global Tumor Immune Cell Therapy Consumption Value and Market Share by Type (2021-2026)
- 4.2 Global Tumor Immune Cell Therapy Market Forecast by Type (2027-2032)

5 MARKET SIZE SEGMENT BY APPLICATION

- 5.1 Global Tumor Immune Cell Therapy Consumption Value Market Share by Application (2021-2026)
- 5.2 Global Tumor Immune Cell Therapy Market Forecast by Application (2027-2032)

6 NORTH AMERICA

- 6.1 North America Tumor Immune Cell Therapy Consumption Value by Type (2021-2032)

6.2 North America Tumor Immune Cell Therapy Market Size by Application (2021-2032)

6.3 North America Tumor Immune Cell Therapy Market Size by Country

6.3.1 North America Tumor Immune Cell Therapy Consumption Value by Country (2021-2032)

6.3.2 United States Tumor Immune Cell Therapy Market Size and Forecast (2021-2032)

6.3.3 Canada Tumor Immune Cell Therapy Market Size and Forecast (2021-2032)

6.3.4 Mexico Tumor Immune Cell Therapy Market Size and Forecast (2021-2032)

7 EUROPE

7.1 Europe Tumor Immune Cell Therapy Consumption Value by Type (2021-2032)

7.2 Europe Tumor Immune Cell Therapy Consumption Value by Application (2021-2032)

7.3 Europe Tumor Immune Cell Therapy Market Size by Country

7.3.1 Europe Tumor Immune Cell Therapy Consumption Value by Country (2021-2032)

7.3.2 Germany Tumor Immune Cell Therapy Market Size and Forecast (2021-2032)

7.3.3 France Tumor Immune Cell Therapy Market Size and Forecast (2021-2032)

7.3.4 United Kingdom Tumor Immune Cell Therapy Market Size and Forecast (2021-2032)

7.3.5 Russia Tumor Immune Cell Therapy Market Size and Forecast (2021-2032)

7.3.6 Italy Tumor Immune Cell Therapy Market Size and Forecast (2021-2032)

8 ASIA-PACIFIC

8.1 Asia-Pacific Tumor Immune Cell Therapy Consumption Value by Type (2021-2032)

8.2 Asia-Pacific Tumor Immune Cell Therapy Consumption Value by Application (2021-2032)

8.3 Asia-Pacific Tumor Immune Cell Therapy Market Size by Region

8.3.1 Asia-Pacific Tumor Immune Cell Therapy Consumption Value by Region (2021-2032)

8.3.2 China Tumor Immune Cell Therapy Market Size and Forecast (2021-2032)

8.3.3 Japan Tumor Immune Cell Therapy Market Size and Forecast (2021-2032)

8.3.4 South Korea Tumor Immune Cell Therapy Market Size and Forecast (2021-2032)

8.3.5 India Tumor Immune Cell Therapy Market Size and Forecast (2021-2032)

8.3.6 Southeast Asia Tumor Immune Cell Therapy Market Size and Forecast (2021-2032)

8.3.7 Australia Tumor Immune Cell Therapy Market Size and Forecast (2021-2032)

9 SOUTH AMERICA

9.1 South America Tumor Immune Cell Therapy Consumption Value by Type (2021-2032)

9.2 South America Tumor Immune Cell Therapy Consumption Value by Application (2021-2032)

9.3 South America Tumor Immune Cell Therapy Market Size by Country

9.3.1 South America Tumor Immune Cell Therapy Consumption Value by Country (2021-2032)

9.3.2 Brazil Tumor Immune Cell Therapy Market Size and Forecast (2021-2032)

9.3.3 Argentina Tumor Immune Cell Therapy Market Size and Forecast (2021-2032)

10 MIDDLE EAST & AFRICA

10.1 Middle East & Africa Tumor Immune Cell Therapy Consumption Value by Type (2021-2032)

10.2 Middle East & Africa Tumor Immune Cell Therapy Consumption Value by Application (2021-2032)

10.3 Middle East & Africa Tumor Immune Cell Therapy Market Size by Country

10.3.1 Middle East & Africa Tumor Immune Cell Therapy Consumption Value by Country (2021-2032)

10.3.2 Turkey Tumor Immune Cell Therapy Market Size and Forecast (2021-2032)

10.3.3 Saudi Arabia Tumor Immune Cell Therapy Market Size and Forecast (2021-2032)

10.3.4 UAE Tumor Immune Cell Therapy Market Size and Forecast (2021-2032)

11 MARKET DYNAMICS

11.1 Tumor Immune Cell Therapy Market Drivers

11.2 Tumor Immune Cell Therapy Market Restraints

11.3 Tumor Immune Cell Therapy Trends Analysis

11.4 Porters Five Forces Analysis

11.4.1 Threat of New Entrants

11.4.2 Bargaining Power of Suppliers

11.4.3 Bargaining Power of Buyers

11.4.4 Threat of Substitutes

11.4.5 Competitive Rivalry

12 INDUSTRY CHAIN ANALYSIS

- 12.1 Tumor Immune Cell Therapy Industry Chain
- 12.2 Tumor Immune Cell Therapy Upstream Analysis
- 12.3 Tumor Immune Cell Therapy Midstream Analysis
- 12.4 Tumor Immune Cell Therapy Downstream Analysis

13 RESEARCH FINDINGS AND CONCLUSION

14 APPENDIX

- 14.1 Methodology
- 14.2 Research Process and Data Source
- 14.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global Tumor Immune Cell Therapy Consumption Value by Type, (USD Million), 2021 & 2025 & 2032

Table 2. Global Tumor Immune Cell Therapy Consumption Value by Application, (USD Million), 2021 & 2025 & 2032

Table 3. Global Tumor Immune Cell Therapy Consumption Value by Region (2021-2026) & (USD Million)

Table 4. Global Tumor Immune Cell Therapy Consumption Value by Region (2027-2032) & (USD Million)

Table 5. MEDINET Co Company Information, Head Office, and Major Competitors

Table 6. MEDINET Co Major Business

Table 7. MEDINET Co Tumor Immune Cell Therapy Product and Solutions

Table 8. MEDINET Co Tumor Immune Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 9. MEDINET Co Recent Developments and Future Plans

Table 10. Erytech Company Information, Head Office, and Major Competitors

Table 11. Erytech Major Business

Table 12. Erytech Tumor Immune Cell Therapy Product and Solutions

Table 13. Erytech Tumor Immune Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 14. Erytech Recent Developments and Future Plans

Table 15. Seta Clinic Group Company Information, Head Office, and Major Competitors

Table 16. Seta Clinic Group Major Business

Table 17. Seta Clinic Group Tumor Immune Cell Therapy Product and Solutions

Table 18. Seta Clinic Group Tumor Immune Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 19. Takeda Company Information, Head Office, and Major Competitors

Table 20. Takeda Major Business

Table 21. Takeda Tumor Immune Cell Therapy Product and Solutions

Table 22. Takeda Tumor Immune Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 23. Takeda Recent Developments and Future Plans

Table 24. SBI Holdings Company Information, Head Office, and Major Competitors

Table 25. SBI Holdings Major Business

Table 26. SBI Holdings Tumor Immune Cell Therapy Product and Solutions

Table 27. SBI Holdings Tumor Immune Cell Therapy Revenue (USD Million), Gross

Margin and Market Share (2021-2026)

Table 28. SBI Holdings Recent Developments and Future Plans

Table 29. Oxford BioTherapeutics Company Information, Head Office, and Major Competitors

Table 30. Oxford BioTherapeutics Major Business

Table 31. Oxford BioTherapeutics Tumor Immune Cell Therapy Product and Solutions

Table 32. Oxford BioTherapeutics Tumor Immune Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 33. Oxford BioTherapeutics Recent Developments and Future Plans

Table 34. Fate Therapeutics Company Information, Head Office, and Major Competitors

Table 35. Fate Therapeutics Major Business

Table 36. Fate Therapeutics Tumor Immune Cell Therapy Product and Solutions

Table 37. Fate Therapeutics Tumor Immune Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 38. Fate Therapeutics Recent Developments and Future Plans

Table 39. Gilead Sciences Company Information, Head Office, and Major Competitors

Table 40. Gilead Sciences Major Business

Table 41. Gilead Sciences Tumor Immune Cell Therapy Product and Solutions

Table 42. Gilead Sciences Tumor Immune Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 43. Gilead Sciences Recent Developments and Future Plans

Table 44. Novartis Company Information, Head Office, and Major Competitors

Table 45. Novartis Major Business

Table 46. Novartis Tumor Immune Cell Therapy Product and Solutions

Table 47. Novartis Tumor Immune Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 48. Novartis Recent Developments and Future Plans

Table 49. Osiris Company Information, Head Office, and Major Competitors

Table 50. Osiris Major Business

Table 51. Osiris Tumor Immune Cell Therapy Product and Solutions

Table 52. Osiris Tumor Immune Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 53. Osiris Recent Developments and Future Plans

Table 54. Vericel Corporation Company Information, Head Office, and Major Competitors

Table 55. Vericel Corporation Major Business

Table 56. Vericel Corporation Tumor Immune Cell Therapy Product and Solutions

Table 57. Vericel Corporation Tumor Immune Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 58. Vericel Corporation Recent Developments and Future Plans

Table 59. Fujifilm Cellular Dynamics Company Information, Head Office, and Major Competitors

Table 60. Fujifilm Cellular Dynamics Major Business

Table 61. Fujifilm Cellular Dynamics Tumor Immune Cell Therapy Product and Solutions

Table 62. Fujifilm Cellular Dynamics Tumor Immune Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 63. Fujifilm Cellular Dynamics Recent Developments and Future Plans

Table 64. JCR Pharmaceuticals Company Information, Head Office, and Major Competitors

Table 65. JCR Pharmaceuticals Major Business

Table 66. JCR Pharmaceuticals Tumor Immune Cell Therapy Product and Solutions

Table 67. JCR Pharmaceuticals Tumor Immune Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 68. JCR Pharmaceuticals Recent Developments and Future Plans

Table 69. Beike Biotechnology Company Information, Head Office, and Major Competitors

Table 70. Beike Biotechnology Major Business

Table 71. Beike Biotechnology Tumor Immune Cell Therapy Product and Solutions

Table 72. Beike Biotechnology Tumor Immune Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 73. Beike Biotechnology Recent Developments and Future Plans

Table 74. Golden Meditech Company Information, Head Office, and Major Competitors

Table 75. Golden Meditech Major Business

Table 76. Golden Meditech Tumor Immune Cell Therapy Product and Solutions

Table 77. Golden Meditech Tumor Immune Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 78. Golden Meditech Recent Developments and Future Plans

Table 79. Guanhao Biotech Company Information, Head Office, and Major Competitors

Table 80. Guanhao Biotech Major Business

Table 81. Guanhao Biotech Tumor Immune Cell Therapy Product and Solutions

Table 82. Guanhao Biotech Tumor Immune Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 83. Guanhao Biotech Recent Developments and Future Plans

Table 84. Beroni Group Company Information, Head Office, and Major Competitors

Table 85. Beroni Group Major Business

Table 86. Beroni Group Tumor Immune Cell Therapy Product and Solutions

Table 87. Beroni Group Tumor Immune Cell Therapy Revenue (USD Million), Gross

Margin and Market Share (2021-2026)

Table 88. Beroni Group Recent Developments and Future Plans

Table 89. Legend Biotech Company Information, Head Office, and Major Competitors

Table 90. Legend Biotech Major Business

Table 91. Legend Biotech Tumor Immune Cell Therapy Product and Solutions

Table 92. Legend Biotech Tumor Immune Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 93. Legend Biotech Recent Developments and Future Plans

Table 94. Global Tumor Immune Cell Therapy Revenue (USD Million) by Players (2021-2026)

Table 95. Global Tumor Immune Cell Therapy Revenue Share by Players (2021-2026)

Table 96. Breakdown of Tumor Immune Cell Therapy by Company Type (Tier 1, Tier 2, and Tier 3)

Table 97. Market Position of Players in Tumor Immune Cell Therapy, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025

Table 98. Head Office of Key Tumor Immune Cell Therapy Players

Table 99. Tumor Immune Cell Therapy Market: Company Product Type Footprint

Table 100. Tumor Immune Cell Therapy Market: Company Product Application Footprint

Table 101. Tumor Immune Cell Therapy New Market Entrants and Barriers to Market Entry

Table 102. Tumor Immune Cell Therapy Mergers, Acquisition, Agreements, and Collaborations

Table 103. Global Tumor Immune Cell Therapy Consumption Value (USD Million) by Type (2021-2026)

Table 104. Global Tumor Immune Cell Therapy Consumption Value Share by Type (2021-2026)

Table 105. Global Tumor Immune Cell Therapy Consumption Value Forecast by Type (2027-2032)

Table 106. Global Tumor Immune Cell Therapy Consumption Value by Application (2021-2026)

Table 107. Global Tumor Immune Cell Therapy Consumption Value Forecast by Application (2027-2032)

Table 108. North America Tumor Immune Cell Therapy Consumption Value by Type (2021-2026) & (USD Million)

Table 109. North America Tumor Immune Cell Therapy Consumption Value by Type (2027-2032) & (USD Million)

Table 110. North America Tumor Immune Cell Therapy Consumption Value by Application (2021-2026) & (USD Million)

Table 111. North America Tumor Immune Cell Therapy Consumption Value by Application (2027-2032) & (USD Million)

Table 112. North America Tumor Immune Cell Therapy Consumption Value by Country (2021-2026) & (USD Million)

Table 113. North America Tumor Immune Cell Therapy Consumption Value by Country (2027-2032) & (USD Million)

Table 114. Europe Tumor Immune Cell Therapy Consumption Value by Type (2021-2026) & (USD Million)

Table 115. Europe Tumor Immune Cell Therapy Consumption Value by Type (2027-2032) & (USD Million)

Table 116. Europe Tumor Immune Cell Therapy Consumption Value by Application (2021-2026) & (USD Million)

Table 117. Europe Tumor Immune Cell Therapy Consumption Value by Application (2027-2032) & (USD Million)

Table 118. Europe Tumor Immune Cell Therapy Consumption Value by Country (2021-2026) & (USD Million)

Table 119. Europe Tumor Immune Cell Therapy Consumption Value by Country (2027-2032) & (USD Million)

Table 120. Asia-Pacific Tumor Immune Cell Therapy Consumption Value by Type (2021-2026) & (USD Million)

Table 121. Asia-Pacific Tumor Immune Cell Therapy Consumption Value by Type (2027-2032) & (USD Million)

Table 122. Asia-Pacific Tumor Immune Cell Therapy Consumption Value by Application (2021-2026) & (USD Million)

Table 123. Asia-Pacific Tumor Immune Cell Therapy Consumption Value by Application (2027-2032) & (USD Million)

Table 124. Asia-Pacific Tumor Immune Cell Therapy Consumption Value by Region (2021-2026) & (USD Million)

Table 125. Asia-Pacific Tumor Immune Cell Therapy Consumption Value by Region (2027-2032) & (USD Million)

Table 126. South America Tumor Immune Cell Therapy Consumption Value by Type (2021-2026) & (USD Million)

Table 127. South America Tumor Immune Cell Therapy Consumption Value by Type (2027-2032) & (USD Million)

Table 128. South America Tumor Immune Cell Therapy Consumption Value by Application (2021-2026) & (USD Million)

Table 129. South America Tumor Immune Cell Therapy Consumption Value by Application (2027-2032) & (USD Million)

Table 130. South America Tumor Immune Cell Therapy Consumption Value by Country

(2021-2026) & (USD Million)

Table 131. South America Tumor Immune Cell Therapy Consumption Value by Country (2027-2032) & (USD Million)

Table 132. Middle East & Africa Tumor Immune Cell Therapy Consumption Value by Type (2021-2026) & (USD Million)

Table 133. Middle East & Africa Tumor Immune Cell Therapy Consumption Value by Type (2027-2032) & (USD Million)

Table 134. Middle East & Africa Tumor Immune Cell Therapy Consumption Value by Application (2021-2026) & (USD Million)

Table 135. Middle East & Africa Tumor Immune Cell Therapy Consumption Value by Application (2027-2032) & (USD Million)

Table 136. Middle East & Africa Tumor Immune Cell Therapy Consumption Value by Country (2021-2026) & (USD Million)

Table 137. Middle East & Africa Tumor Immune Cell Therapy Consumption Value by Country (2027-2032) & (USD Million)

Table 138. Global Key Players of Tumor Immune Cell Therapy Upstream (Raw Materials)

Table 139. Global Tumor Immune Cell Therapy Typical Customers

List Of Figures

LIST OF FIGURES

Figure 1. Tumor Immune Cell Therapy Picture

Figure 2. Global Tumor Immune Cell Therapy Consumption Value by Type, (USD Million), 2021 & 2025 & 2032

Figure 3. Global Tumor Immune Cell Therapy Consumption Value Market Share by Type in 2025

Figure 4. Immune Checkpoint Inhibitors

Figure 5. Chimeric Antigen Receptor T-cell Therapy

Figure 6. Tumor-Infiltrating Lymphocytes Therapy

Figure 7. Cancer Vaccines

Figure 8. Bispecific Antibodies

Figure 9. Cytokine Therapy

Figure 10. Global Tumor Immune Cell Therapy Consumption Value by Application, (USD Million), 2021 & 2025 & 2032

Figure 11. Tumor Immune Cell Therapy Consumption Value Market Share by Application in 2025

Figure 12. Hematological Tumors Picture

Figure 13. Solid Tumors Picture

Figure 14. Global Tumor Immune Cell Therapy Consumption Value, (USD Million): 2021 & 2025 & 2032

Figure 15. Global Tumor Immune Cell Therapy Consumption Value and Forecast (2021-2032) & (USD Million)

Figure 16. Global Market Tumor Immune Cell Therapy Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)

Figure 17. Global Tumor Immune Cell Therapy Consumption Value Market Share by Region (2021-2032)

Figure 18. Global Tumor Immune Cell Therapy Consumption Value Market Share by Region in 2025

Figure 19. North America Tumor Immune Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 20. Europe Tumor Immune Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 21. Asia-Pacific Tumor Immune Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 22. South America Tumor Immune Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 23. Middle East & Africa Tumor Immune Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 24. Company Three Recent Developments and Future Plans

Figure 25. Global Tumor Immune Cell Therapy Revenue Share by Players in 2025

Figure 26. Tumor Immune Cell Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025

Figure 27. Market Share of Tumor Immune Cell Therapy by Player Revenue in 2025

Figure 28. Top 3 Tumor Immune Cell Therapy Players Market Share in 2025

Figure 29. Top 6 Tumor Immune Cell Therapy Players Market Share in 2025

Figure 30. Global Tumor Immune Cell Therapy Consumption Value Share by Type (2021-2026)

Figure 31. Global Tumor Immune Cell Therapy Market Share Forecast by Type (2027-2032)

Figure 32. Global Tumor Immune Cell Therapy Consumption Value Share by Application (2021-2026)

Figure 33. Global Tumor Immune Cell Therapy Market Share Forecast by Application (2027-2032)

Figure 34. North America Tumor Immune Cell Therapy Consumption Value Market Share by Type (2021-2032)

Figure 35. North America Tumor Immune Cell Therapy Consumption Value Market Share by Application (2021-2032)

Figure 36. North America Tumor Immune Cell Therapy Consumption Value Market Share by Country (2021-2032)

Figure 37. United States Tumor Immune Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 38. Canada Tumor Immune Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 39. Mexico Tumor Immune Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 40. Europe Tumor Immune Cell Therapy Consumption Value Market Share by Type (2021-2032)

Figure 41. Europe Tumor Immune Cell Therapy Consumption Value Market Share by Application (2021-2032)

Figure 42. Europe Tumor Immune Cell Therapy Consumption Value Market Share by Country (2021-2032)

Figure 43. Germany Tumor Immune Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 44. France Tumor Immune Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 45. United Kingdom Tumor Immune Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 46. Russia Tumor Immune Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 47. Italy Tumor Immune Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 48. Asia-Pacific Tumor Immune Cell Therapy Consumption Value Market Share by Type (2021-2032)

Figure 49. Asia-Pacific Tumor Immune Cell Therapy Consumption Value Market Share by Application (2021-2032)

Figure 50. Asia-Pacific Tumor Immune Cell Therapy Consumption Value Market Share by Region (2021-2032)

Figure 51. China Tumor Immune Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 52. Japan Tumor Immune Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 53. South Korea Tumor Immune Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 54. India Tumor Immune Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 55. Southeast Asia Tumor Immune Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 56. Australia Tumor Immune Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 57. South America Tumor Immune Cell Therapy Consumption Value Market Share by Type (2021-2032)

Figure 58. South America Tumor Immune Cell Therapy Consumption Value Market Share by Application (2021-2032)

Figure 59. South America Tumor Immune Cell Therapy Consumption Value Market Share by Country (2021-2032)

Figure 60. Brazil Tumor Immune Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 61. Argentina Tumor Immune Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 62. Middle East & Africa Tumor Immune Cell Therapy Consumption Value Market Share by Type (2021-2032)

Figure 63. Middle East & Africa Tumor Immune Cell Therapy Consumption Value Market Share by Application (2021-2032)

Figure 64. Middle East & Africa Tumor Immune Cell Therapy Consumption Value

Market Share by Country (2021-2032)

Figure 65. Turkey Tumor Immune Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 66. Saudi Arabia Tumor Immune Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 67. UAE Tumor Immune Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 68. Tumor Immune Cell Therapy Market Drivers

Figure 69. Tumor Immune Cell Therapy Market Restraints

Figure 70. Tumor Immune Cell Therapy Market Trends

Figure 71. Porters Five Forces Analysis

Figure 72. Tumor Immune Cell Therapy Industrial Chain

Figure 73. Methodology

Figure 74. Research Process and Data Source

I would like to order

Product name: Global Tumor Immune Cell Therapy Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Product link: <https://marketpublishers.com/r/G487C1DD8422EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G487C1DD8422EN.html>